These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15995633)

  • 1. Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer.
    Lyzogubov V; Khozhaenko Y; Usenko V; Antonjuk S; Ovcharenko G; Tikhonkova I; Filonenko V
    Exp Oncol; 2005 Jun; 27(2):141-4. PubMed ID: 15995633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors.
    Filonenko VV; Tytarenko R; Azatjan SK; Savinska LO; Gaydar YA; Gout IT; Usenko VS; Lyzogubov VV
    Exp Oncol; 2004 Dec; 26(4):294-9. PubMed ID: 15627062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of S6K1 and S6K2 expression in endometrial adenocarcinomas.
    Lyzogubov VV; Lytvyn DI; Dudchenko TM; Lubchenko NV; Pogrybniy PV; Nespryadko SV; Vinnitska AB; Usenko VS; Gout IT; Filonenko VV
    Exp Oncol; 2004 Dec; 26(4):287-93. PubMed ID: 15627061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of S6K1 and S6K2 expression in human breast tumors.
    Savinska LO; Lyzogubov VV; Usenko VS; Ovcharenko GV; Gorbenko ON; Rodnin MV; Vudmaska MI; Pogribniy PV; Kyyamova RG; Panasyuk GG; Nemazanyy IO; Malets MS; Palchevskyy SS; Gout IT; Filonenko VV
    Eksp Onkol; 2004 Mar; 26(1):24-30. PubMed ID: 15112576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AgNOR, Ki-67 and PCNA expression in fibroepithelial tumours of the breast in correlation with morphological features.
    Barwijuk-Machała M; Musiatowicz B; Cylwik J; Reszeć J; Augustynowicz A
    Folia Morphol (Warsz); 2004 Feb; 63(1):133-5. PubMed ID: 15039920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR.
    Biesterfeld S; Klüppel D; Koch R; Schneider S; Steinhagen G; Mihalcea AM; Schröder W
    J Pathol; 1998 May; 185(1):25-31. PubMed ID: 9713356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer.
    Guzińska-Ustymowicz K; Pryczynicz A; Kemona A; Czyzewska J
    Anticancer Res; 2009 Aug; 29(8):3049-52. PubMed ID: 19661314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers.
    Gee JM; Douglas-Jones A; Hepburn P; Sharma AK; McClelland RA; Ellis IO; Nicholson RI
    J Pathol; 1995 Nov; 177(3):285-93. PubMed ID: 8551391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 65 kDa oncofetal protein (p65), proliferating cell nuclear antigen (PCNA) and Ki67 expression in breast cancer patients.
    Niewiadomska H; Mirowski M; Stempien M; Olborski B; Blonski JZ; Hanausek M; Wierzbicki R
    Neoplasma; 1998; 45(4):216-22. PubMed ID: 9890664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
    Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
    Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic significance of proliferating cell nuclear antigen and Ki-67 in malignant ovarian germ cell tumors.
    Liu FS; Chen JT; Liu SC; Shih A; Shih RT; Ho ES
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):695-702. PubMed ID: 10533299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
    Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
    Yu CC; Dublin EA; Camplejohn RS; Levison DA
    Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
    Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of proliferating cell nuclear antigen and Ki-67 expression by cytomegalovirus infection.
    Mate JL; Ariza A; Muñoz A; Molinero JL; López D; Navas-Palacios JJ
    J Pathol; 1998 Mar; 184(3):279-82. PubMed ID: 9614380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
    Markiewski M; Domagała W
    Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of proliferating markers Ki-67, PCNA in gastric cancers.
    Czyzewska J; Guzińska-Ustymowicz K; Lebelt A; Zalewski B; Kemona A
    Rocz Akad Med Bialymst; 2004; 49 Suppl 1():64-6. PubMed ID: 15638377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
    Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
    Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Ki-67 and PCNA as proliferating markers in prostate cancer.
    Sulik M; Guzińska-Ustymowicz K
    Rocz Akad Med Bialymst; 2002; 47():262-9. PubMed ID: 12533969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.